What is the recommended dosing schedule and side‑effect monitoring for pomalidomide, dexamethasone, and belantamab mafodotin in an adult with relapsed/refractory multiple myeloma who has already been treated with a proteasome inhibitor, an immunomodulatory drug (e.g., lenalidomide), and an anti‑CD38 antibody?

Pomalidomide, Dexamethasone, and Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

Critical Context: Belantamab Mafodotin Withdrawal and Current Status

Belantamab mafodotin was withdrawn from the US market in November 2022 after failing to demonstrate superiority over pomalidomide/dexamethasone in the DREAMM-3 trial, though it remains available through compassionate use programs and is listed as "useful in certain circumstances" by NCCN for heavily pretreated patients. 1, 2

• The DREAMM-3 trial showed median PFS of 11.2 months with belantamab mafodotin versus 7 months with pomalidomide/dexamethasone, but this difference was not statistically significant (HR 1.03; 95% CI 0.72-1.47) 1, 2
• Patients already receiving belantamab mafodotin through the FDA Risk Evaluation and Mitigation Strategy (REMS) program can continue via compassionate use 1

Recommended Dosing Schedule

Pomalidomide + Dexamethasone (Standard Doublet)

For patients with relapsed/refractory MM after ≥2 prior therapies including lenalidomide and bortezomib, pomalidomide 4 mg orally on days 1-21 of each 28-day cycle combined with dexamethasone 40 mg weekly (or 20 mg weekly in maintenance) is the established regimen. 1, 3, 4

• Pomalidomide: 4 mg orally daily on days 1-21 of each 28-day cycle 3, 4, 5
• Dexamethasone: 40 mg weekly (days 1,8,15,22) during active treatment 5, 6
• Dexamethasone: 20 mg weekly during maintenance phase 4
• Continue until disease progression or unacceptable toxicity 4

Belantamab Mafodotin Dosing (If Used)

If belantamab mafodotin is considered in the triplet combination (available only through compassionate use), the dose is 2.5 mg/kg IV on day 1 of cycle 1, then 1.9 mg/kg IV on day 1 of subsequent 28-day cycles. 6

• Initial dose: 2.5 mg/kg intravenously on day 1 of cycle 1 6
• Subsequent doses: 1.9 mg/kg intravenously on day 1 of cycles 2 onward 6
• Combined with pomalidomide 4 mg days 1-21 and dexamethasone 40 mg weekly 6

Side Effect Profile and Monitoring

Hematologic Toxicities (Most Common)

Grade 3-4 neutropenia (51-62.5%), thrombocytopenia, and anemia are the most frequent adverse events requiring regular complete blood count monitoring. 3, 4, 5

• Neutropenia: Grade 3-4 occurs in 51-62.5% of patients on pomalidomide/dexamethasone regimens 4, 5
• Thrombocytopenia: Common grade 3-4 toxicity requiring dose modifications 3
• Anemia: Frequent grade 3-4 event 3
• Lymphopenia: Grade 3-4 in 35% of patients 4

Monitor CBC weekly during the first 8 weeks, then monthly thereafter; hold pomalidomide for ANC <500/μL or platelets <25,000/μL. 3

Belantamab Mafodotin-Specific Toxicities

Keratopathy is the signature toxicity of belantamab mafodotin, occurring in 51.5-93% of patients (grade 3-4 in 21-33%), requiring mandatory ophthalmologic evaluation before each dose through the REMS program. 1, 2

• Keratopathy: 51.5-93% all grades; 21-33% grade 3-4 1, 2
• Thrombocytopenia: Grade 3-4 in 33-67% (significantly reduced with dose reduction: 33% vs 67%, p=0.048) 2
• Anemia: Common grade 3-4 toxicity 1
• Blurred vision: Reported as severe/very severe in 43% of patients receiving belantamab mafodotin combinations 6

Mandatory ophthalmologic examination is required before each belantamab mafodotin dose; dose delays or reductions are necessary for grade 2-3 keratopathy. 2

Infectious Complications

Grade 3-4 infections occur in 13-31% of patients, with pneumonia being particularly common (13.4%), requiring aggressive antimicrobial prophylaxis. 4, 5

• Grade 3-4 infections: 13-31% of patients 4, 5
• Pneumonia: 13.4% grade 3-4 5
• Implement prophylaxis for Pneumocystis jirovecii, herpes zoster, and consider antibacterial prophylaxis in high-risk patients 5

Non-Hematologic Toxicities

Fatigue is reported as severe/very severe in 35-38% of patients across both pomalidomide-based and belantamab-containing regimens. 6

• Fatigue: 35-38% severe/very severe 6
• Nausea and gastrointestinal symptoms: manageable with antiemetics 7
• Peripheral neuropathy: less common with pomalidomide than with proteasome inhibitors 7

Monitoring Algorithm

Baseline Assessments

• Complete blood count with differential 3
• Comprehensive metabolic panel 7
• Ophthalmologic examination (if using belantamab mafodotin) 2
• Pregnancy test (pomalidomide is teratogenic) 3
• Thrombosis risk assessment 7

During Treatment

• CBC weekly for first 8 weeks, then monthly 3
• Ophthalmologic exam before each belantamab dose (if applicable) 2
• Monthly metabolic panel 7
• Infection surveillance at each visit 5
• Thromboprophylaxis with aspirin or LMWH based on risk factors 7

Clinical Efficacy Context

Pomalidomide/dexamethasone achieves overall response rates of 26-31% in dual-refractory (lenalidomide/bortezomib) patients, with limited cross-resistance to lenalidomide. 1, 3

• Overall response rate: 26-31% in lenalidomide/bortezomib dual-refractory patients 3
• When combined with daratumumab in earlier lines (1-2 prior therapies): ORR 77.7% (76.2% in lenalidomide-refractory) 5
• Median PFS with pomalidomide/dexamethasone maintenance: 33.2 months in first relapse 4

Belantamab mafodotin monotherapy showed 31-34% ORR in triple-class refractory patients, but failed to demonstrate superiority over pomalidomide/dexamethasone in head-to-head comparison. 1, 2

Common Pitfalls and How to Avoid Them

• Pitfall: Delaying dose modifications for cytopenias

  • Solution: Implement protocol-driven dose holds for ANC <500/μL or platelets <25,000/μL 3

• Pitfall: Inadequate thromboprophylaxis with immunomodulatory agents

  • Solution: All patients require aspirin 81-325 mg daily or LMWH if additional risk factors present 7

• Pitfall: Missing keratopathy progression with belantamab mafodotin

  • Solution: Mandatory ophthalmologic evaluation before every dose; proactive dose delays allow continued treatment in most patients 2

• Pitfall: Inadequate infection prophylaxis in heavily pretreated patients

  • Solution: Universal Pneumocystis and herpes zoster prophylaxis; consider antibacterial prophylaxis during neutropenic periods 5

Alternative Considerations for This Population

Given belantamab mafodotin's withdrawal and limited availability, CAR-T therapy (ciltacabtagene or idecabtagene) should be strongly considered for eligible patients after ≥4 prior therapies, offering superior response rates (73-97% ORR) compared to belantamab mafodotin (31-34% ORR). 2, 8

• CAR-T (cilta-cel): 97% ORR, 67% stringent CR in heavily pretreated patients 8
• CAR-T (ide-cel): 73% ORR, 33% CR or better 8
• Bispecific antibodies (teclistamab): 62% ORR, 58.5% PFS at 9 months 2